SymBiosis Capital Partners, LLC
Long book
$52.8M
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
-31.9%
SPY +14.8%
Turnover
58%
of book per quarter
Strategy in plain words
auto-generated from filingsSymBiosis Capital Partners, LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $52.8M US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: EVOMMUNE INC, INVENTIVA SA - ADR, WAVE LIFE SCIENCES LTD, RANI THERAPEUTICS HOLDINGS-A, CLENE INC.
We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
-14.8%
Q1 2026
-31.9%
Sector allocation
Healthcare 100%